Mounjaro contains the active ingredient Tirzepatide.
It is a groundbreaking weight loss injection, offering a clinically proven method for managing obesity. Developed by the pharmaceutical company Eli Lilly, it is administered once a week via a single-use injection. It works by regulating appetite and metabolism, providing a targeted and sustainable weight loss solution.
Mounjaro is licensed for long-term weight management when combined with a reduced-calorie diet and increased physical activity. It is suitable for adults with a starting BMI of 30 or higher (classed as obesity), or 27 or higher (overweight) if they also have a weight-related health condition.
Tirzepatide functions as both a glucose-dependent insulinotropic polypeptide (GIP) receptor agonist and a glucagon-like peptide-1 (GLP-1) receptor agonist. This dual-action mechanism helps suppress appetite, reduce hunger, and facilitate weight loss.
Originally approved for managing type 2 diabetes, Mounjaro has now been authorised by the MHRA for use in weight management in adults and will be available in the UK by the end of the month.
Developed with cutting-edge research, Mounjaro targets the biological processes involved in appetite control, food intake, and insulin sensitivity. By mimicking the actions of key hormones, it helps decrease hunger and improve metabolic health, resulting in significant weight loss and improved markers for conditions like type 2 diabetes and heart disease.
For people in the UK seeking an effective and convenient weight loss solution, Mounjaro offers real potential. Being able to access it online has increased its availability, providing a straightforward route to better health with professional guidance and support.